Study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 presented at Clinical Trials in Alzheimer’s Disease (CTAD) 2020

Alzinova presented the study design of the upcoming first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 on a poster titled: First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of Aβ 1-42. The poster was presented at Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, November 4-7. 2020